russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2113Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONСЛУЧАЙ ДИЛАТАЦИОННОИ КАРДИОМИОПАТИИ У БОЛЬНОГО, ИЗЛЕЧЕННОГО ОТ ОСТРОГО ЛЕЙКОЗАA CASE OF DILATED CARDIOMYOPATHY IN A PATIENT TREATED FROM ACUTE LEUKEMIAПановаТ. Н.PanovaT. N.

Кафедра госпитальной терапии с курсом функциональной диагностики

ЗакляковаЛ. В.ZaklyakovaL. V.

Кафедра госпитальной терапии с курсом функциональной диагностики

КучероваТ. П.KucherovaT. P.

Кафедра госпитальной терапии с курсом функциональной диагностики

КурьяноваЛ. В.KuryanovaL. V.

Кафедра госпитальной терапии с курсом функциональной диагностики

МайороваС. В.MayorovaS. V.

Кафедра госпитальной терапии с курсом функциональной диагностики

УклистаяЕ. А.UklistayaE. A.

Кафедра госпитальной терапии с курсом функциональной диагностики

Астраханская государственная медицинская академияРоссия200128082001047173Copyright © Панова Т.Н., Заклякова Л.В., Кучерова Т.П., Курьянова Л.В., Майорова С.В., Уклистая Е.А., 20012001Панова Т.Н., Заклякова Л.В., Кучерова Т.П., Курьянова Л.В., Майорова С.В., Уклистая Е.А.Panova T.N., Zaklyakova L.V., Kucherova T.P., Kuryanova L.V., Mayorova S.V., Uklistaya E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2113

Случай дилатационнои кардиомиопатии у больного, излеченного отострого лейкоза.

A case of dilated cardiomyopathy in a patient treated from acute leukemia.

ReferencesГершанович М.Л. Осложнения прихимио игормонотерапии злокачественных опухолей. БПВ. М: Медицина; 1982.Гершанович М.Л. Осложнения прихимио игормонотерапии злокачественных опухолей. БПВ. М: Медицина; 1982.Calzas J., Lianes P., Cortes Funes H. Heart pathology of extracardiac origin ( YII ). Heart and neoplasms. Rev.Esp.Cardiol. 1998; 51 (4): 314-331.Calzas J., Lianes P., Cortes Funes H. Heart pathology of extracardiac origin ( YII ). Heart and neoplasms. Rev.Esp.Cardiol. 1998; 51 (4): 314-331.Cordioli E., Tondini C., Pizzi C., Massarelli G. Silent myocardial infarction in a patient treated with radiation therapy and polychemiotherapy for Hodgkinrs lymphoma. Cardiologia 1997; 42 (6): 635-638.Cordioli E., Tondini C., Pizzi C., Massarelli G. Silent myocardial infarction in a patient treated with radiation therapy and polychemiotherapy for Hodgkinrs lymphoma. Cardiologia 1997; 42 (6): 635-638.Ferrans V.J., Clark J.R., Zhang J.Y. et al. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 1997; 39 (10): 928-937.Ferrans V.J., Clark J.R., Zhang J.Y. et al. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 1997; 39 (10): 928-937.Kakadekar F.H., Sandor G.G., Flyer C. et al. Differences in dose scheduling as a factor in the etiology of anthra-cycline-induced cardiotoxicity in Ewing sarcoma patients. Med. Pediatr. Oncol. 1997; 28 (1): 22-26.Kakadekar F.H., Sandor G.G., Flyer C. et al. Differences in dose scheduling as a factor in the etiology of anthra-cycline-induced cardiotoxicity in Ewing sarcoma patients. Med. Pediatr. Oncol. 1997; 28 (1): 22-26.Niitsu N., Kato M./ Shikoshi K., Umeda M. Doxorubicin-induced myocardial damage in elderly patients with hematologic malignancies. Hippon-Ronen-Igakkai-Zasshi 1997; 34 (1): 38-42.Niitsu N., Kato M./ Shikoshi K., Umeda M. Doxorubicin-induced myocardial damage in elderly patients with hematologic malignancies. Hippon-Ronen-Igakkai-Zasshi 1997; 34 (1): 38-42.Weiss M.A., Drullinsky P., Maslak H. et al. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998; 12 (6): 865-868.Weiss M.A., Drullinsky P., Maslak H. et al. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998; 12 (6): 865-868.Jensen B.V., Nielsen S.L., Jensen T.S. Angiotensin converting enzyme inhibitor in treatment of epirubicin induced dilatated cardiomyopathy. Ugerskr.Laeger. 1997; 159(13): 1945-1949.Jensen B.V., Nielsen S.L., Jensen T.S. Angiotensin converting enzyme inhibitor in treatment of epirubicin induced dilatated cardiomyopathy. Ugerskr.Laeger. 1997; 159(13): 1945-1949.Takahashi S., Denvir M.A., Harder L. et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycine) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in «chemically-skinned» rabbit ventricular trabeculae. Jpn.J.Pharmacol. 1998; 76(4): 405-408.Takahashi S., Denvir M.A., Harder L. et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycine) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in «chemically-skinned» rabbit ventricular trabeculae. Jpn.J.Pharmacol. 1998; 76(4): 405-408.Lihshultz S.E. Monitoring for anthracycline cardiotoxity. Pediatrics 1994; 93 (3): 433-437.Lihshultz S.E. Monitoring for anthracycline cardiotoxity. Pediatrics 1994; 93 (3): 433-437.Lipshultz S.E., Colan S.D., Gelber R.D. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N.Engl.J.Med. 1991; 324 (12): 808-815.Lipshultz S.E., Colan S.D., Gelber R.D. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N.Engl.J.Med. 1991; 324 (12): 808-815.

The authors declare that there are no conflicts of interest present.